109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
雾化右美托咪定对女性患者行胸腔镜肺癌根治术后恶心呕吐的影响：一项单中心随机对照试验
Authors Liu X , Zhu H, Zhao Y, Yang Y, Li B, Wei W, Wei L, Zhang J, Zhang W
Received 5 August 2025
Accepted for publication 26 October 2025
Published 12 November 2025 Volume 2025:19 Pages 10061—10073
DOI https://doi.org/10.2147/DDDT.S558129
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Tin Wui Wong
Xinmin Liu,1,* Haipeng Zhu,2,* Yi Zhao,3 Yulong Yang,3 Bing Li,1 Wenxue Wei,4 Li Wei,4 Jiaqiang Zhang,1 Wei Zhang1
1Department of Anesthesiology and Perioperative Medicine, Henan Provincial People’s Hospital, Zhengzhou, People’s Republic of China; 2Department of Anesthesiology, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, People’s Republic of China; 3Department of Anesthesiology and Perioperative Medicine, Henan University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, People’s Republic of China; 4Department of Thoracic Surgery, Henan Provincial People’s Hospital, Zhengzhou, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Wei Zhang, Department of Anesthesiology and Perioperative Medicine, Henan Provincial People’s Hospital, Zhengzhou, Henan, People’s Republic of China, Tel +86-13838299702, Email myhope2005@163.com
Purpose: This study aimed to investigate the effect of nebulized dexmedetomidine on postoperative nausea and vomiting (PONV) in female patients undergoing radical thoracoscopic lung cancer resection.
Patients and Methods: Patients were enrolled and randomized into the nebulized dexmedetomidine group (Dex group) and the normal saline group (NS group). The primary outcome was the overall incidence of PONV within 48 hours postoperatively. Secondary outcomes included the incidence and grade of PONV at multiple postoperative time points (T1: during PACU stay; T2: from PACU discharge to 8 hours postoperatively; T3: 8– 16 hours postoperatively; T4: 16– 24 hours postoperatively; T5: 24– 32 hours postoperatively; T6: 32– 40 hours postoperatively; T7: 40– 48 hours postoperatively), postoperative sore throat (POST), Visual Analogue Scale (VAS) scores at the above time points, use of rescue analgesics and antiemetics, Quality of Recovery 15-item scale (QoR-15) scores et al.
Results: A total of 64 eligible patients were enrolled, with 57 completing the study. There was no statistically significant difference in the overall incidence of PONV within 48 hours postoperatively between two groups. However, the incidence of PONV and POST in the Dex group was significantly lower than that in the NS group at T2. The area under the curve of VAS in the Dex group was significantly lower than that in the NS group within 24 hours and 48 hours postoperatively. The Dex group had a significantly lower rate of rescue analgesic use and higher postoperative QoR-15 scores within 48 hours postoperatively compared with the NS group.
Conclusion: Nebulized inhalation of 1 μg/kg dexmedetomidine preoperatively can reduce the incidence of early postoperative PONV, enhance postoperative analgesia, alleviate postoperative sore throat, and improve postoperative recovery quality in female patients undergoing radical lung cancer surgery.
Trial Number and Registry Url: Registration number, ChiCTR2400086070; https://www.chictr.org.cn/bin/project/edit?pid=235076.
Keywords: postoperative nausea and vomiting, nebulized inhalation, female, lung cancer surgery, dexmedetomidine
1Department of Anesthesiology and Perioperative Medicine, Henan Provincial People’s Hospital, Zhengzhou, People’s Republic of China; 2Department of Anesthesiology, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, People’s Republic of China; 3Department of Anesthesiology and Perioperative Medicine, Henan University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, People’s Republic of China; 4Department of Thoracic Surgery, Henan Provincial People’s Hospital, Zhengzhou, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Wei Zhang, Department of Anesthesiology and Perioperative Medicine, Henan Provincial People’s Hospital, Zhengzhou, Henan, People’s Republic of China, Tel +86-13838299702, Email myhope2005@163.com
Purpose: This study aimed to investigate the effect of nebulized dexmedetomidine on postoperative nausea and vomiting (PONV) in female patients undergoing radical thoracoscopic lung cancer resection.
Patients and Methods: Patients were enrolled and randomized into the nebulized dexmedetomidine group (Dex group) and the normal saline group (NS group). The primary outcome was the overall incidence of PONV within 48 hours postoperatively. Secondary outcomes included the incidence and grade of PONV at multiple postoperative time points (T1: during PACU stay; T2: from PACU discharge to 8 hours postoperatively; T3: 8– 16 hours postoperatively; T4: 16– 24 hours postoperatively; T5: 24– 32 hours postoperatively; T6: 32– 40 hours postoperatively; T7: 40– 48 hours postoperatively), postoperative sore throat (POST), Visual Analogue Scale (VAS) scores at the above time points, use of rescue analgesics and antiemetics, Quality of Recovery 15-item scale (QoR-15) scores et al.
Results: A total of 64 eligible patients were enrolled, with 57 completing the study. There was no statistically significant difference in the overall incidence of PONV within 48 hours postoperatively between two groups. However, the incidence of PONV and POST in the Dex group was significantly lower than that in the NS group at T2. The area under the curve of VAS in the Dex group was significantly lower than that in the NS group within 24 hours and 48 hours postoperatively. The Dex group had a significantly lower rate of rescue analgesic use and higher postoperative QoR-15 scores within 48 hours postoperatively compared with the NS group.
Conclusion: Nebulized inhalation of 1 μg/kg dexmedetomidine preoperatively can reduce the incidence of early postoperative PONV, enhance postoperative analgesia, alleviate postoperative sore throat, and improve postoperative recovery quality in female patients undergoing radical lung cancer surgery.
Trial Number and Registry Url: Registration number, ChiCTR2400086070; https://www.chictr.org.cn/bin/project/edit?pid=235076.
Keywords: postoperative nausea and vomiting, nebulized inhalation, female, lung cancer surgery, dexmedetomidine